View More Recent Stories
-
William Blair Reiterates Outperform Rating on Aldeyra Therapeutics (ALDX)
-
Aldeyra Therapeutics (ALDX) PT Raised to $10 at Jones Trading
-
Aldeyra Therapeutics (ALDX) Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
-
Aldeyra Therapeutics (ALDX) Halted, News Pending


